论文部分内容阅读
目的:探讨阿德福韦酯与拉米夫定治疗乙型肝炎肝硬化的疗效差异。方法:分析2013年1月至2015年1月信阳市中心医院收治的45例乙型肝炎肝硬化患者的临床资料。结果:两组患者治疗期间,乙型肝炎病毒(HBV)脱氧核糖核酸(DNA)转阴率明显升高,且观察组明显高于对照组,组间比较,差异具有统计学意义(P<0.05)。观察组患者,应用阿德福韦酯过程中,患者出现轻微心悸1例,恶心2例,消化不良1例,不良反应发生率为18.18%,与对照组比较,差异无统计学意义(P>0.05)。结论:阿德福韦酯治疗乙型肝炎肝硬化临床效果优于拉米夫定。
Objective: To investigate the difference between adefovir dipivoxil and lamivudine in the treatment of hepatitis B cirrhosis. Methods: Clinical data of 45 patients with hepatitis B cirrhosis admitted from January 2013 to January 2015 in Xinyang Central Hospital were analyzed. Results: During the treatment period, the DNA negative rate of hepatitis B virus (HBV) was significantly higher in the observation group than in the control group, with significant difference between the two groups (P <0.05 ). In the observation group, one case of mild palpitations, two cases of nausea, one case of dyspepsia and 18.18% of adverse reactions occurred in patients with adefovir dipivoxil. There was no significant difference between the two groups (P> 0.05). Conclusion: Adefovir dipivoxil treatment is superior to lamivudine in the treatment of hepatitis B cirrhosis.